Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|April 16, 2020
Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving ImmunotherapyJahan J Mohiuddin, Brian Chu, Andrea Facciabene, et al.
JCO Precision Oncology|July 27, 2023
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerCharu Aggarwal, Melina E Marmarelis, Wei-Ting Hwang, et al.
Advances in Radiation Oncology|October 14, 2021
Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the AnusJahan J Mohiuddin, Krishan R Jethwa, Nikhil Grandhi, et al.
European Urology|October 29, 2021
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate CancerDaniel J Lee, Ryan Hausler, Anh N Le, et al.
Clinical Lung Cancer|January 9, 2024
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab ConsolidationAdam Barsouk, Cole Friedes, Michelle Iocolano, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2018
A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancerJacob E Shabason, Jerry Chen, Smith Apisarnthanarax, et al.
International Journal of Radiation Oncology, Biology, Physics|August 24, 2023
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent ChemoradiationNikhil Yegya-Raman, Cole Friedes, Sang Ho Lee, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancersNabamita Boruah, David Hoyos, Renyta Moses, et al.
Nature Communications|May 21, 2026
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancersNabamita Boruah, David Hoyos, Renyta Moses, et al.
Clinical Lung Cancer|April 19, 2023
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health SystemNikhil Yegya-Raman, Cole Friedes, Lova Sun, et al.
Pageof 6